Senores Pharma | Business Upturn

Senores Pharma shares fall sharply over 4% despite strong Q3 results; Revenue rises 69.4% YoY to Rs 174.5 crore, net profit jumps 88%

Aman Shukla — Tue, 20 Jan 2026 08:12:51 +0000

Shares of Senores Pharma declined sharply by over 4% in trade, even as the company reported a robust set of financial results for the third quarter, marked by strong growth across revenue and profitability parameters. As of 1:45 PM, the shares were trading 3.70% lower at Rs 776.10.

For the December quarter, Senores Pharma posted a significant jump in net profit, which rose 88% year-on-year to ₹32 crore, compared with ₹17 crore in the same period last year.

Revenue performance remained strong, with Q3 revenue increasing 69.4% year-on-year to ₹174.5 crore, up from ₹103 crore in the corresponding quarter of the previous financial year. The growth reflects healthy execution across the company’s key business segments during the reporting period.

Operating metrics also showed notable improvement. EBITDA for the quarter stood at ₹54 crore, compared with ₹25.4 crore a year ago. As a result, EBITDA margins expanded to 31% from 25% on a year-on-year basis, indicating better cost efficiency and operating performance.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Senores Pharma Q3 Results: Revenue jumps 69.4% YoY to Rs 174.5 crore, net profit up 88%

Aman Shukla — Tue, 20 Jan 2026 08:06:45 +0000

Senores Pharma reported a strong set of financial numbers for the third quarter, delivering sharp year-on-year growth across profitability and revenue metrics.

The company’s net profit nearly doubled during the quarter, rising 88% to ₹32 crore compared with ₹17 crore in the corresponding period last year. The improvement in earnings reflects better operating leverage and a higher scale of business execution during the quarter.

Revenue for Q3 increased significantly by 69.4% year-on-year to ₹174.5 crore, up from ₹103 crore in the same quarter of the previous financial year. The strong top-line growth indicates robust performance across key business segments during the period under review.

Operating performance also strengthened notably, with EBITDA rising to ₹54 crore compared with ₹25.4 crore a year ago. EBITDA margins expanded to 31% from 25% on a year-on-year basis, highlighting improved operational efficiency and cost management.

Senores Pharma’s subsidiary Havix completes USFDA inspection with 3 observations

Aman Shukla — Mon, 28 Jul 2025 10:28:04 +0000

Senores Pharmaceuticals announced that its material subsidiary, Havix Group Inc. (doing business as Aavis Pharmaceuticals), successfully completed a routine inspection by the U.S. Food and Drug Administration (USFDA). The inspection was conducted at Havix’s manufacturing facility located at 9488 Jackson Trail Road, Hoschton, Georgia, USA, from July 21 to July 25, 2025.

The USFDA issued three Form 483 observations following the inspection. According to the company, all the observations are procedural and minor in nature. Havix is committed to addressing the points raised and will submit its response to the USFDA within the stipulated 15-day period.

In the exchnge filings, the company shared, “We hereby inform that Havix Group Inc. D/B/A Aavis Pharmaceuticals (“Havix”), a Material Subsidiary of the Company situated at 9488 Jackson Trail Road, Hoschton, Georgia 30548, USA has completed the United States Food & Drug Administration (“USFDA”) inspection of its manufacturing facility from July 21, 2025 to July 25, 2025 with 3 (Three), 483 observations.”

This development reaffirms Senores Pharma’s ongoing commitment to maintaining global quality standards at its facilities.

Senores Pharma shares jump 12% after Q1 revenue surges 72% YoY to Rs 138 crore, EBIDTA up 60% YoY

Aman Shukla — Thu, 24 Jul 2025 04:01:39 +0000

Shares of Senores Pharmaceuticals surged over 12% in Thursday’s trade after the company reported a strong set of numbers for the first quarter of FY26, backed by robust growth across both Regulated and Emerging Markets.

The company posted a total income of ₹138 crore, marking a solid 72% year-on-year (YoY) growth for Q1FY26. EBITDA came in at ₹34 crore, up 60% YoY, while Profit After Tax (PAT) stood at ₹21 crore.

Senores, known for its focus on specialty and complex pharmaceutical products, continues to expand its global footprint, especially in tightly regulated and competitive markets.

Business Highlights:

In the Regulated Markets, revenue for Q1FY26 stood at ₹90 crore, up 69% YoY. The EBITDA margin for this segment remained strong at 35.5%.
The company currently has:

24 Own commercial products
70 Approved ANDAs
57 Pipeline products (including 37 with Competitive Generic Therapy opportunities)
27 CDMO/CMO commercial products
53 CDMO/CMO pipeline products

In the Emerging Markets, Q1FY26 revenue rose 32% YoY to ₹29 crore, with an EBITDA margin of 6%. The company has:

308 Registered products
719 products under registration
Operations spanning over 40 countries

With a diversified product basket and expanding market presence, Senores appears well-positioned for sustained growth in the coming quarters—reflected in the strong investor interest seen today.

Senores Pharma shares surge 3.3% as company commences operations at new Greenfield API facility in Rajpur

Aman Shukla — Thu, 27 Feb 2025 04:07:25 +0000

Senores Pharma (SPL) shares jumped 3% after the company officially commenced operations at its cutting-edge Active Pharmaceutical Ingredient (API) manufacturing facility in Rajpur, Kadi, Mehsana, Gujarat. As of 9:35 AM, the shares were trading 3.32% higher at Rs 566.85.

Spanning an impressive 230,000 sq. ft., the new plant has an installed capacity of approximately 100 metric tons per annum. This expansion marks a significant milestone for Senores Pharma, reinforcing its position in the pharmaceutical industry.

As the company’s second API manufacturing facility, this greenfield project enhances production capabilities and ensures the supply of high-purity APIs to meet growing industry demands.

Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, said, We are delighted to commence operations at our greenfield state-of-the-art API facility atMehsana. Commissioning of this API facility will help Senores broaden its offerings andstrengthen its competitiveness in the Regulated Markets, especially in the CDMO/CMObusiness.”

Senores Pharma shares opened at ₹562.00 and hit a high of ₹585.00 before dipping to ₹555.50. The stock remains below its 52-week high of ₹644.80 but well above its low of ₹435.25.

Senores Pharma IPO: How to check allotment, latest GMP and other IPO details

Aditya Bhagchandani — Thu, 26 Dec 2024 02:40:46 +0000

The allotment of Senores Pharmaceuticals IPO shares is expected to be finalized today, December 26, 2024, following an overwhelming subscription of 93.41 times on the final day of bidding.

Senores Pharma IPO Details

Issue Size: ₹582.11 crore
Price Band: ₹372-₹391 per share
Total Bids: 79.72 crore shares
Shares Available: 85.34 lakh shares
Retail Subscription: 89.23x
Listing Date: December 30, 2024
Grey Market Premium (GMP): ₹230 (60% premium over issue price)

The strong demand was primarily driven by Qualified Institutional Buyers (QIBs) and Non-Institutional Investors (NIIs), indicating robust investor confidence in the Ahmedabad-based company.

How to Check Senores Pharma IPO Allotment Status

Via Link Intime (Registrar’s Website)

Visit Link Intime India.
Select Senores Pharma from the dropdown menu.
Enter your PAN, Application Number, or DP Client ID.
Click Submit.
The allotment status will be displayed on the screen.

Via NSE (National Stock Exchange)

Go to the NSE IPO Allotment page: NSE IPO Login.
Sign up or log in with your details.
Select Senores Pharma from the IPO list.
Enter your IPO Application Number.
Click Submit to view your allotment status.

Via BSE (Bombay Stock Exchange)

Visit BSE IPO Allotment.
Click on Investor Services > Status of Issue Application.
Choose Equity in the issue type dropdown.
Select Senores Pharma from the dropdown list.
Enter your PAN or Application Number.
Click Search to view the allotment status.

Senores Pharma IPO GMP Update

Market observers report that the grey market premium for Senores Pharma shares stands at ₹230, reflecting a 58.82% listing gain. This indicates strong market anticipation for a successful debut.

Key Dates

Allotment Finalization: December 26, 2024
Listing Date: December 30, 2024

Investors who applied for the IPO are advised to check their allotment status using the methods mentioned above. Stay tuned for further updates as the listing date approaches.